Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Black Diamond Therapeutics Inc BDTX

Healthcare Biotechnology
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat... see more

Recent & Breaking News (NDAQ:BDTX)

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2024

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 1, 2024

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

GlobeNewswire October 7, 2024

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

GlobeNewswire September 23, 2024

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

GlobeNewswire September 22, 2024

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire September 14, 2024

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

GlobeNewswire August 8, 2024

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2024

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 1, 2024

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2024

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 24, 2024

Black Diamond Therapeutics Announces Changes to Board of Directors

GlobeNewswire April 11, 2024

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

GlobeNewswire April 7, 2024

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire April 3, 2024

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 12, 2024

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

GlobeNewswire March 5, 2024

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

GlobeNewswire January 4, 2024

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

GlobeNewswire December 13, 2023